Demographics and screening characteristics for ≥1-year studies in patients with COPD by baseline blood eosinophil level and treatment group: TRISTAN (SFCB3024)
| FP/SAL | FP | SAL | Placebo | |||||
|---|---|---|---|---|---|---|---|---|
| Characteristic | <2% | ≥2% | <2% | ≥2% | <2% | ≥2% | <2% | ≥2% |
| n | 93 | 248 | 94 | 266 | 86 | 269 | 81 | 266 |
| Age, mean (SD) | 63.1 (8.49) | 62.8 (8.80) | 63.3 (8.64) | 63.7 (8.57) | 64.4 (8.38) | 62.8 (8.47) | 60.3 (8.23) | 64.3 (8.50) |
| Male (%) | 77 | 76 | 61 | 72 | 56 | 74 | 68 | 76 |
| Current smokers (%) | 56 | 50 | 64 | 49 | 57 | 50 | 62 | 44 |
| Pack-years, median (range) | 40.0 (10–124) | 40.0 (10–159) | 35.5 (10–105) | 40.0 (10–110) | 44.5 (10–140) | 40.0 (10–135) | 41.2 (12–131) | 40.0 (10–150) |
| Post-BD FEV1% predicted, mean (SD) | 52.4 (14.51) | 51.0 (14.58) | 50.5 (13.89) | 51.8 (14.46) | 49.1 (13.91) | 50.4 (13.95) | 49.1 (14.50)* | 51.3 (13.98) |
| FEV1% reversibility, mean (SD) | 3.4 (3.38) | 3.9 (3.60) | 2.5 (3.25) | 3.9 (5.95) | 3.6 (3.85) | 3.3 (3.72) | 3.6 (3.52)* | 3.5 (4.59) |
*n=80.
BD, bronchodilator; FP, fluticasone propionate; SAL, salmeterol.